Literature DB >> 8394714

PCR diagnosis of primary herpesvirus type I in poliomyelitis-like paralysis and respiratory tract disease.

M G Kyllerman1, S Herner, T B Bergström, S E Ekholm.   

Abstract

Successful and rapid recovery of HSV-1 DNA from the cerebrospinal fluid after amplification by polymerase chain reaction was obtained in a 7-year-old boy with subtotal and permanent upper extremity paralysis with rapid onset and magnetic resonance imaging evidence of cervical cord involvement. Early administration of intravenous acyclovir probably limited neuronal loss. The clinical course and outcome of this disorder best conformed with what has been described as poliomyelitis-like paralysis associated with respiratory tract infection (Hopkins syndrome).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8394714     DOI: 10.1016/0887-8994(93)90091-p

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  4 in total

1.  Rapid onset transverse myelitis in adolescence: implications for pathogenesis and prognosis.

Authors:  J M Wilmshurst; M C Walker; K R Pohl
Journal:  Arch Dis Child       Date:  1999-02       Impact factor: 3.791

2.  Poliomyelitis-like syndrome following asthmatic attack (Hopkins' syndrome)--recovery associated with i.v. gamma globulin treatment.

Authors:  H A Cohen; A Ashkenasi; H Ring; R Weiss; B Wolach; G Paret; A Barzilai
Journal:  Infection       Date:  1998 Jul-Aug       Impact factor: 3.553

Review 3.  HSV-1 brain infection by the olfactory nerve route and virus latency and reactivation may cause learning and behavioral deficiencies and violence in children and adults: a point of view.

Authors:  Y Becker
Journal:  Virus Genes       Date:  1995       Impact factor: 2.332

4.  Herpes Simplex Virus Type 2 Myelitis: Case Report and Review of the Literature.

Authors:  Raffaele Nardone; Viviana Versace; Francesco Brigo; Frediano Tezzon; Giulio Zuccoli; Slaven Pikija; Larissa Hauer; Johann Sellner
Journal:  Front Neurol       Date:  2017-05-10       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.